Palleon Pharmaceuticals Inc. CEO and founder Jim Broderick told BioWorld that the just-raised $100 million in series B money leaves the firm well positioned to push its lead oncology compound into the clinic next year, bolstered by a widely gathered team of experts – “almost a consortium” – in glycan mediation.